We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CASTLE-HTx.
- Authors
Havránek, Štěpán
- Abstract
The CASTLE HTx trial showed a significant reduction in the primary composite endpoint in patients with advanced heart failure with reduced ejection fraction and atrial fibrillation who were treated with catheter ablation in addition to optimal medical treatment of heart failure. Catheter ablation was compared with optimal medical treatment alone. The primary endpoint was a composite of death from any cause, implantation of a left ventricular assist device, and urgent heart transplantation.
- Subjects
CATHETER ablation; HEART failure; ATRIAL fibrillation; HEART assist devices; HEART failure patients; THERAPEUTICS
- Publication
Intervencní a Akutní Kardiologie, 2024, Vol 23, Issue 2/3, p136
- ISSN
1213-807X
- Publication type
Academic Journal
- DOI
10.36290/kar.2024.015